NCT05731297

Brief Summary

In conflict situations, sexual violence (SV) used can take various forms, including rape and female genital mutilation (FGM). SV is used as a strategic weapon to shake, terrorize, and displace communities and thus take control of a particular population or territory. For two decades, the Great Lakes region of Central Africa, which includes the eastern part of the Democratic Republic of the Congo (DRC), has experienced a high degree of instability due to various armed conflicts. The attacks on civilians are illustrated by SV. In 2011, studies in DRC estimated that 1 150 women are raped every day and that 30% of women have experienced conflict-related sexual violence (CRSV) over the past 16 years. In addition to physical suffering, survivors of CRSV must live with psychological consequences. Traumatic fistula, one of the most extreme consequences of SV, is well described in the literature, as its surgical management. In contrast, the literature and the government illustrate a lack of accurate data on the physical consequences such as pelvic dysfunction and psychologic disorders following these attacks. To be able to put in place adequate care, it is necessary to identify the conditions and needs of the victims.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
742

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2021

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

January 20, 2023

Completed
27 days until next milestone

First Posted

Study publicly available on registry

February 16, 2023

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

February 16, 2023

Status Verified

February 1, 2023

Enrollment Period

4 years

First QC Date

January 20, 2023

Last Update Submit

February 7, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Urinary aspects

    Urinary aspects will be assessed by one questionnaire: International Consultation on Incontinence Questionnaire Female Lower Urinary Tract SymptomsModules (ICIQ-FLUTS)

    At the test time

  • Sexual aspects

    Sexual aspects will be assessed by one questionnaire: Female Sexual Function Index (FSFI)

    At the test time

  • Pelvic and Perineal aspect

    Pelvic and Perineal aspect will be assessed by clinical examination made by a women assistant of the research team, physiotherapist expert on pelvic floor field • Examen of observation: presence of scars, lesions, inflammation, type of FGM as described by WHO classification and types of scars during external exam; Perineal pain, intensity and localization with Haslam and Laycock ring of continence, pelvic floor muscle tone with the Reissing tone scale which have a good interrater reliability for intra-vaginal manual assessment of pubococcygeus tone for expert examinator. Laycock's power, endurance, repetitions, fast contractions, every contraction timed (PERFECT) scale will be used for pelvic floor muscle assessment. The PERFECT scheme has demonstrated good reliability and validity as an assessment tool. .

    At the test time

  • Ano-rectal aspect

    Two questionnaires will be used; one to assess anal incontinence (AI) and one for constipation * The St. Mark's Incontinence Score (SMIS) * The Knowles, Eccersley, Scott Symptom Score (KESS

    At the test time

Secondary Outcomes (2)

  • Psychological aspect: will assessing with be PCL-5 questionnaire

    At the test time

  • Quality of Life (QoL)

    At the test time

Other Outcomes (1)

  • Sociodemographic characteristic data

    At the test time

Study Arms (2)

women victims of CRSV

* Inclusion criteria: Women victims of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study. * Exclusion criteria: Pregnant women and women under 18 years old.

women without a history of CRSV

* Inclusion criteria: women without a history of CRSV living in the places of enrolment in RDC, aged over 18 years and giving their consent to participate to this study. * Exclusion criteria: Pregnant women and women under 18 years old.

Eligibility Criteria

Age18 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women in RDC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Betty Miangindula

Kinshasa, Democratic Republic of the Congo

RECRUITING

Central Study Contacts

Jeanne Bertuit, PhD

CONTACT

Jeanne.bertuit Bertuit, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 20, 2023

First Posted

February 16, 2023

Study Start

September 1, 2021

Primary Completion

September 1, 2025

Study Completion

September 1, 2025

Last Updated

February 16, 2023

Record last verified: 2023-02

Locations